

## **NOVITA HEALTHCARE (ASX: NHL) - Formerly AVEXA (ASX: AVX) Share Sale Facility for holders of less than a “Marketable Parcel” Closes**

Novita Healthcare Limited (the Company) announces that the Share Sale Facility (the Facility) of ordinary shares for shareholders who hold less than a "marketable parcel" closed on 12 December 2016.

The Company provided the Facility to shareholders of who hold less than a "marketable parcel" (defined under the ASX Listing Rules as a parcel of securities of not less than \$500) to sell their shares without incurring any brokerage or handling costs that could otherwise make a sale of their shares uneconomic. Less than a “marketable parcel” was determined on the closing price of Avexa Limited (now Novita Healthcare Limited) shares on 24 October 2016, being 2.8 cents, and represents a holding of 17,856 shares or less. Details of the Facility were provided in a letter and accompanying Share Sale Facility Form lodged with ASX on 25 October 2016 and forwarded to eligible shareholders.

As at market close on the 12 December 2016 there were 8,679,553 ordinary shares, held by 6,096 shareholders to be sold (Sale Shares). There were 762 shareholders that elected to retain their shares, representing 2,016,275 shares. The sale consideration for each holding sold pursuant to the Facility will be determined by reference to the Sale Price and the number of shares held on 12 December 2016. The Sale Price is to be determined as the sum of the sales proceeds of all the Sale Shares sold divided by the sum of all the Sale Shares sold pursuant to the Facility.

The Sale Shares will be sold by Bell Potter Securities Limited (Bell Potter) and may be sold on the terms, in the manner (whether on-market through ASX, by private treaty or through a share sale process established on behalf of the Company) and at the time or times determined by the Directors in consultation with Bell Potter. The Sale Price may be different from the sale price appearing in the media or on the ASX on a day a sale occurs, and may not be the best execution price on the trading day or trading days that Sale Shares are sold or at any other time during the operation of the Facility. The Sale Price will depend on a number of factors, including market conditions at the time of sale.

For all parcels of share for which the sale consideration is \$2 or less, the proceeds will be donated to the Autism Spectrum Australia. There were 198 shareholders who also opted to donate the proceeds of the sale of their parcel of shares to Autism Spectrum Australia. For all other shareholders who participated in the Facility the sale consideration will be available for distribution following settlement of the sale of all Sale Shares through the Facility or otherwise as soon as it is practicable. Australian residents will be paid their sale consideration in Australian dollars only by direct credit to an account held with an Australian Financial Institution in the name of the shareholder shown on the Share Sale Facility Form sent to each eligible shareholder. Non-resident holders who do not have an account with an Australian Financial Institution will be paid in Australian dollars by cheque. Australian resident shareholders who have participated in the Facility but have not advised details of an account held with an Australian Financial Institution will be required to provide account details to enable a direct credit payment to be made.

Account details need to be advised to the Company's share registry, Automic Registry Services, as follows:

Online: <https://investor.automic.com.au>

Email: [hello@automic.com.au](mailto:hello@automic.com.au)

By facsimile: +61 2 8583 3040

By mail: Automic, PO Box 2226, Strawberry Hills NSW 2012

All sale consideration amounts less than \$20 which remain unclaimed at the conclusion of the statutory period for unclaimed monies will be donated to Autism Spectrum Australia.

By making this Facility available the Company also expects to reduce the administrative costs associated with maintaining a large number of small holdings.

For any questions you may have in relation to this announcement or the Facility should be directed to Novita Healthcare Limited (Telephone 1300 082 013 or Email: [avexa@avexa.com.au](mailto:avexa@avexa.com.au)) or Automic Registry Services (see contact details above).

**John Osborne,**  
Company Secretary

**END**

***For more information:***

Iain Kirkwood  
Chairman  
Mob: +61 408 473 496  
Novita Healthcare: 1300 082 013  
Email: [avexa@avexa.com.au](mailto:avexa@avexa.com.au)

---

**About Novita Healthcare Limited**

Novita Healthcare is a Melbourne-based medical technology company. Its flagship program is the revolutionary and innovative TALI system, which uses cutting edge technology to diagnose and treat cognitive problems such as attention difficulties in early childhood.

**About the TALI system**

TALI Health Pty Ltd (100% owned by Novita Healthcare) has the exclusive global license to the TALI Technology together with the option to acquire the TALI Technology outright. TALI is seeking to position itself as the global leader in the diagnosis and treatment of attention difficulties, particularly in children with developmental disorders, such as autism. The TALI Technology is a result of ground-breaking research pioneered over twenty years by internationally renowned neuroscientist Professor Kim Cornish and her team at Monash University. The front end of the TALI Technology is an attention assessment and training program (accessed via a software application prescribed by healthcare professionals), delivered on a computerized tablet (or similar). The back end of the TALI Technology is a Cloud based, centralised secure data collection, analysis and report system.